Skip to main content
Advertising

Originally published August 11, 2014 at 5:48 AM | Page modified August 12, 2014 at 3:14 AM

  • Share:
           
  • Comments
  • Print

Madrid hospital: Spanish priest with Ebola dies

A Spanish missionary priest being treated for Ebola died Tuesday in a Madrid hospital amid a worldwide ethical debate over who should get an experimental Ebola drug.


Associated Press

Reader Comments
Hide / Show comments
I'm trying to understand why the unapproved experimental drug for Ebola is getting so much attention. Until a couple... MORE
Wasn't so long ago the west was being criticized for using africans as "guinea pigs" for HIV vaccine. These drugs are... MORE

advertising

MADRID —

A Spanish missionary priest being treated for Ebola died Tuesday in a Madrid hospital amid a worldwide ethical debate over who should get an experimental Ebola drug.

Spain's Health Ministry said Monday it had obtained a course of the U.S.-made experimental Ebola drug ZMapp to treat Father Miguel Pajares, 75.

Pajares died Tuesday at Carlos III Hospital, the hospital and his order said. The hospital would not confirm that he had been treated with the drug, but his order said earlier that he would be.

He is one of only three Ebola patients thought to have received the experimental treatment. The others are two Americans evacuated to Atlanta. The vast majority of those sickened by the virus have been Africans.

The World Health Organization says 1,013 people have died so far in the Ebola outbreak in West Africa and authorities have recorded 1,848 suspected, probable or confirmed cases of the killer virus. The virus was detected in Guinea in March and has since spread to Sierra Leone, Liberia and possibly Nigeria.

Pajares had been treating people with Ebola at the San Jose de Monrovia Hospital in Liberia when he became ill, and was evacuated to Spain on Thursday. He worked for the San Juan de Dios hospital order, a Spain-based Catholic humanitarian group that runs hospitals around the world.

On Tuesday, the U.N. health agency denied reports from Liberia that it had authorized the experimental Ebola drug for that hard-hit nation.

"We were not involved in transferring the serum and we will not be involved in any future transfers of it," said Gregory Hartl, a WHO spokesman. "WHO doesn't have any role in handing out the serum or any other experimental medicines."

WHO was holding a news conference later Tuesday to discuss the ethical issues surrounding unproven Ebola drugs and vaccines.

Liberia also backed away from its earlier claim that President Barack Obama had approved the use of experimental Ebola drugs for two Liberian doctors.

In a statement Tuesday, a U.K.-based public relations firm representing the Liberian government said the experimental Ebola treatment would be arriving within the next 48 hours.

"The two doctors gave their consent, themselves being medical professionals, for the drug to be administered," the statement said. "The drugmaker has agreed to supply a sufficient amount of this drug only for these two patients."

Also Tuesday, Liberian President Ellen Johnson Sirleaf suspended all travel by executive branch officials for one month. She also ordered those already abroad to return home within a week "or be considered as abandoning their jobs," according to a statement from her press secretary.

Most airlines flying in and out of the Liberian capital of Monrovia have suspended flights amid the unprecedented health crisis.

___

Associated Press writer Jonathan Paye-Layleh in Monrovia, Liberia contributed to this report.



Want unlimited access to seattletimes.com? Subscribe now!

News where, when and how you want it

Email Icon

Career Center Blog

Career Center Blog

Bad email habits to break today


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►